The Relationship between a New Biomarker of Vagal Neuroimmunomodulation and Survival in Two Fatal Cancers

por Gidron, Y., De Couck, M., Schallier, D., De Greve, J., Van Laethem, J. L., Maréchal, R.
Publicado 2018

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

por Demols, A, Peeters, M, Polus, M, Marechal, R, Gay, F, Monsaert, E, Hendlisz, A, Van Laethem, J L
Publicado 2006

DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

por Drouillard, A, Puleo, F, Bachet, J B, Ouazzani, S, Calomme, A, Demetter, P, Verset, G, Van Laethem, J L, Maréchal, R
Publicado 2016

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

por Maréchal, R, Demetter, P, Nagy, N, Berton, A, Decaestecker, C, Polus, M, Closset, J, Devière, J, Salmon, I, Van Laethem, J-L
Publicado 2009

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

por Maréchal, R, Demetter, P, Nagy, N, Berton, A, Decaestecker, C, Polus, M, Closset, J, Devière, J, Salmon, I, Van Laethem, J-L
Publicado 2010